Hello, welcome to live coronavirus coverage with me, Helen Sullivan.
As always, you can find me on Twitter @helenrsullivan.
Canada is expected to receive a significant amount of vaccines in the coming months, through a platform designed to maximize supply to poor countries, according to a new forecast, despite reserving the highest amount of doses per person in the world through agreements with pharmaceutical companies.
Globe and Mail reports that Canada will be the only G7 country in the world to accept vaccines from the scheme.
My colleagues Michael Safi and Leyland Cecco report that Canada has the right to receive vaccines under the Covax scheme, in which advance purchases by wealthy nations are used to finance vaccine development and subsidize doses for poorer countries.
But Ottawa also led the world in direct business with pharmaceutical companies to secure its own supply, reserving enough to cover approximately 9.6 doses per person, according to the Guardian’s analysis.
More on that soon. For now, here are the other important recent developments:
- Belgian regulators are the latest in Europe to advise against giving the Oxford / AstraZeneca vaccine to the elderly due to the lack of data on its effectiveness.
- Switzerland denied approval for the Oxford / AstraZeneca Covid vaccine, your drug regulator said today.
- Leaders in Europe are recklessly risking their own public health by using autonomous punctuation to attack the UK’s coronavirus vaccine launch UK health experts warned. “The views of Europe’s politicians contrast with the scientific view reached by the European regulator,” said a former chief regulator of medicines.
- New coronavirus infections in Greece increased by over 1,000 for the second consecutive day, with health officials adding 1,151 to the country’s count after a month of the daily number remaining in the three-digit range.
- Veterinarians in Germany trained sniffer dogs to detect coronavirus in human saliva samples with 94% accuracy.
- The Covax installation scheme aims to distribute at least 330m of doses in the first half of 2021, its co-leaders announced on Wednesday. It also struck a deal with the Serum Institute of India for up to 1.1 billion doses of AstraZeneca and Novavax vaccines for $ 3 per dose for low- and middle-income countries.
- AstraZeneca and the University of Oxford intend to develop a state-of-the-art vaccine to combat new variants as early as autumn, a senior executive at the manufacturer told Reuters.